Gene: MYO5C

55930
-
myosin VC
protein-coding
15q21.2
Ensembl:ENSG00000128833 MIM:610022 Vega:OTTHUMG00000172630 UniprotKB:Q9NQX4
NC_000015.10
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.489e-1 (AD)  6.020e-2 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg27633342chr15:52588279MYO5C1.000e-9Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMEM670.759
KNTC10.753
AGO40.751
NKTR0.749
SYCP20.746
RECK0.745
ADAM170.744
ZNF354B0.742
MLLT100.736
ATXN70.735

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
S100A1-0.331
HMX1-0.326
HES6-0.314
KLRC2-0.298
BTBD17-0.287
SLC25A48-0.284
DIAPH3-0.283
LHPP-0.277
C7orf61-0.276
HOMER3-0.267

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5C mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5C mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of MYO5C mRNA21420995
D020106AcrylamideAcrylamide results in increased expression of MYO5C mRNA28959563
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of MYO5C mRNA24449571
D001151ArsenicArsenic affects the methylation of MYO5C gene25304211
C006632arsenic trioxideMYO5C protein results in decreased susceptibility to arsenic trioxide20707922
D001379AzathioprineAzathioprine results in decreased expression of MYO5C mRNA22623647
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MYO5C mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MYO5C mRNA21839799
C006780bisphenol Abisphenol A results in increased expression of MYO5C mRNA25594700
C006780bisphenol Abisphenol A results in decreased expression of MYO5C mRNA25181051
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of MYO5C mRNA15336504
C018475butyraldehydebutyraldehyde results in decreased expression of MYO5C mRNA26079696
D002392Catechin[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of MYO5C mRNA24763279
C018021cobaltous chloridecobaltous chloride results in decreased expression of MYO5C mRNA19376846
D019327Copper SulfateCopper Sulfate results in decreased expression of MYO5C mRNA19549813
C030973cupric oxidecupric oxide results in decreased expression of MYO5C mRNA22077320
D003471CuprizoneCuprizone results in increased expression of MYO5C mRNA26577399
D016572CyclosporineCyclosporine results in decreased expression of MYO5C mRNA25562108
C007262deoxynivalenoldeoxynivalenol results in decreased expression of MYO5C mRNA26763390
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of MYO5C mRNA]27941970
D002945CisplatinCisplatin results in decreased expression of MYO5C mRNA27392435
D004041Dietary FatsDietary Fats results in increased expression of MYO5C mRNA18042831
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of MYO5C mRNA24535843
C051904dinophysistoxin 1dinophysistoxin 1 results in decreased expression of MYO5C mRNA28939011
D004237DiuronDiuron results in decreased expression of MYO5C mRNA21551480
C511402Grape Seed Proanthocyanidins[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of MYO5C mRNA24763279
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of MYO5C mRNA24796395
C410337K 7174K 7174 results in decreased expression of MYO5C mRNA24086573
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of MYO5C mRNA"25554681
D009532NickelNickel results in decreased expression of MYO5C mRNA24768652|2558310
C029938nickel sulfatenickel sulfate results in decreased expression of MYO5C mRNA22714537
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of MYO5C mRNA25729387
C030110oxaliplatinoxaliplatin results in decreased expression of MYO5C mRNA25729387
D000073878Palm OilPalm Oil results in increased expression of MYO5C mRNA18042831
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5C mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of MYO5C mRNA26272509
D011794QuercetinQuercetin results in decreased expression of MYO5C mRNA18095365
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of MYO5C mRNA21427059
D012822Silicon DioxideSilicon Dioxide results in decreased expression of MYO5C mRNA25351596
D012906SmokeSmoke results in decreased expression of MYO5C mRNA21095227
D053260SootSoot results in decreased expression of MYO5C mRNA26551751
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MYO5C mRNA21632981
C009495titanium dioxidetitanium dioxide results in increased expression of MYO5C mRNA23409001
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of MYO5C mRNA28065790
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of MYO5C mRNA25729387
D019772TopotecanTopotecan results in decreased expression of MYO5C mRNA25729387
D014212TretinoinTretinoin results in decreased expression of MYO5C mRNA23724009
C012589trichostatin Atrichostatin A results in increased expression of MYO5C mRNA24935251
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of MYO5C mRNA"26179874
D014520UrethaneUrethane results in decreased expression of MYO5C mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO5C mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MYO5C mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of MYO5C mRNA23179753|2493525
D014635Valproic AcidValproic Acid results in increased expression of MYO5C mRNA21427059
D014638VanadatesVanadates results in decreased expression of MYO5C mRNA22714537
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of MYO5C gene25560391
C025643vinclozolinvinclozolin affects the expression of MYO5C mRNA19015723

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003777microtubule motor activity-IEA-  
GO:0005516calmodulin binding-IEA-  
GO:0005524ATP binding-IEA-  
GO:0008017microtubule binding-IEA-  
GO:0051015actin filament binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007018microtubule-based movement-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0016459myosin complex-IEA-  
GO:0070062extracellular exosome-HDA23533145  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29325019Deep molecular phenotypes link complex disorders and physiological insult to CpG methylation. (2018 Mar 15)Zaghlool SBHum Mol Genet